SIGN UP
LOG IN
MARKET
VNDA
VNDA
Vanda Pharma
NASDAQ
4.050
+0.090
+2.27%
Opening 09:58 12/06 EST
OPEN
3.990
PREV CLOSE
3.960
HIGH
4.055
LOW
3.945
VOLUME
90.70K
TURNOVER
0
52 WEEK HIGH
11.04
52 WEEK LOW
3.295
MARKET CAP
233.00M
P/E (TTM)
20.02
1D
5D
1M
3M
1Y
5Y
Vanda Pharma stock rises after FDA accepts gastroparesis drug for review
Vanda pharma stock rises after fda accepts gastroparesis drug for review. Fda accepted the new drug application for tradipitant, an experimental drug. Tradipitant is a neurokinin 1 antagonist licensed by vanda from eli lilly in 2012. Vanda shares jumped 19% premarket on tuesday.
Seeking Alpha · 1d ago
Vanda Pharmaceuticals Says FDA Accepted New Drug Application For Tradipitant For Treatment Of Gastroparesis
The fda has set september 18, 2024 as the target date for a decision. Tradipitant is the first novel drug to be approved by the fda for gastroparesis in over 40 years. The drug is being tested for the treatment of the disease in the u.s.
Benzinga · 1d ago
Weekly Report: what happened at VNDA last week (1127-1201)?
Weekly Report · 2d ago
Weekly Report: what happened at VNDA last week (1120-1124)?
Weekly Report · 11/27 10:30
The Right Play On Intra-Cellular Therapies
Intra-cellular therapies, inc. Is a mid-cap biopharmaceutical company focused on developing treatments for neuropsychiatric and neurological disorders. The company's commercial asset, caplyta, has achieved significant sales growth in the antipsychotic market. The drug is approved for the treatment of schizophrenia and bipolar depression in adults. Intra-cellular has several other early-to-mid-stage clinical programs in its pipeline.
Seeking Alpha · 11/20 16:49
Weekly Report: what happened at VNDA last week (1113-1117)?
Weekly Report · 11/20 10:28
Weekly Report: what happened at VNDA last week (1106-1110)?
Weekly Report · 11/13 10:23
Vanda Pharma: Current report
Press release · 11/10 15:51
About VNDA
Vanda Pharmaceuticals Inc. (Vanda) is a global biopharmaceutical company focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Vanda's commercial portfolio is comprised of two products, HETLIOZ for the treatment of jet lag disorder, insomnia, delayed sleep phase disorder (DSPD), sleep disturbances in autism spectrum disorder (ASD) and pediatric Non-24 and Fanapt for the treatment of bipolar I disorder and Parkinsons disease psychosis and a long acting injectable (LAI) formulation for the treatment of schizophrenia. In addition, the Company has a range of drugs in development, including Tradipitant (VLY-686), for the treatment of gastroparesis, motion sickness, atopic dermatitis, and Covid-19 pneumonia; VTR-297 for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications, and VQW-765, for the treatment of performance anxiety and psychiatric disorders.
Webull offers Vanda Pharmaceuticals Inc. stock information, including NASDAQ: VNDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VNDA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading VNDA stock methods without spending real money on the virtual paper trading platform.